Real-World PEDD Study Shows Improved Outcomes
A study published in the Journal of Comparative Effectiveness Research highlights the clinical and economic benefits of Pressure-Enabled Drug Delivery (PEDD®) technology in the treatment of solid tumors, demonstrating improved outcomes and charge avoidance.
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in trans-arterial chemoemboliz